Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kalota, Susan
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
CELLEBRATE, NCT03104517 / 2016-002635-15: Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence	Recruiting	3	96	Europe, US	AMDC-USR (iltamiocel), Placebo	Cook MyoSite	Stress Urinary Incontinence	01/25	02/26
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer	Recruiting	1/2	75	US	STM-416	SURGE Therapeutics	Non-muscle-invasive Bladder Cancer	12/25	12/25
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve	Recruiting	1/2	222	Canada, US	EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2	enGene, Inc.	Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	06/25	05/27
NCT04629170: Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria	Completed	1	77	US	SYNB8802, Placebo	Synlogic	Healthy, Enteric Hyperoxaluria	01/23	01/23
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial	Recruiting	N/A	390	US	Active treatment, Sham	Viveve Inc.	Urinary Incontinence, Stress	12/22	12/22
Simpson, Jasmine
NCT04629170: Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria	Completed	1	77	US	SYNB8802, Placebo	Synlogic	Healthy, Enteric Hyperoxaluria	01/23	01/23
NCT04841226: Randomized Study of Silq Urinary Catheter	Completed	N/A	158	US	Long-term indwelling Foley catheter	Silq Technologies Corporation	Biofilm Formation, UTI	03/24	08/24